Quick Answer
RenovoRx, Inc. reported Net Income Loss of -$11.17 million for the year ending 2025.
- RenovoRx, Inc. showed a decrease of -26.7% in Net Income Loss from 2024 to 2025.
- This data is from RenovoRx, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$1.05 million | Q2 2020: -$773.0 thousand | Q3 2020: -$1.10 million | Q1 2021: -$1.15 million | Q2 2021: -$1.31 million | Q3 2021: -$1.51 million | Q1 2022: -$3.00 million | Q2 2022: -$2.59 million | Q3 2022: -$2.14 million | Q1 2023: -$3.26 million | Q2 2023: -$2.33 million | Q3 2023: -$1.42 million | Q1 2024: -$1.08 million | Q2 2024: -$2.39 million | Q3 2024: -$2.47 million | Q1 2025: -$2.42 million | Q2 2025: -$2.90 million | Q3 2025: -$2.91 million.
- Over the full 6 years of available data (2020 to 2025), RenovoRx, Inc.'s Net Income Loss has declined by 194.0%.
- Historical annual values: Fiscal year 2025: -$11.17 million | Fiscal year 2024: -$8.81 million | Fiscal year 2023: -$10.23 million | Fiscal year 2022: -$9.89 million | Fiscal year 2021: -$6.32 million | Fiscal year 2020: -$3.80 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: